FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK/STAT3 Pathway

  • Haixia Liu
    Department of Pathology, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China
    Search for articles by this author
  • Yu Mei
    Department of Breast Surgery, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China
    Search for articles by this author
  • Xiaoshan Ma
    Community health Service Center of Ganshiqiao, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China
    Search for articles by this author
  • Xiaoyan Zhang
    Department of Pharmacy, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China
    Search for articles by this author
  • Wenying Nie
    Address for correspondence: Wenying Nie, Department of Children's Health Care, Jinan Maternity and child care Hospital Affiliated to Shandong First Medical University, No.2, Jianguo Xiaojingsan street, Jinan, 250001, Shandong, P.R. ChinaDepartment of Children's Health Care, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shangdong, P.R. China
    Search for articles by this author



      To explore the expression of frizzled related protein (FRZB) in triple-negative breast cancer (TNBC) and role of FRZB in TNBC cell growth and invasion.


      Breast cancer clinical data were downloaded from the Cancer Genome Atlas. FRZB and early growth response 1 (EGR1) mRNA levels in TNBC were measured by quantitative real-time polymerase chain reaction. FRZB protein level was measured by immunohistochemistry and western blot. Proliferation, migration, and invasion of TNBC cells were detected by colony formation, wound healing, and transwell assay, respectively. The protein levels of EGR1, E-cadherin, N-cadherin, Snail, p-JAK1/JAK1, p-JAK2/JAK2, and p-STAT3/STAT3 were measured by western blot. JASPAR was used to predict the binding site of FRZB and EGR1. The binding ability of FRZB and EGR1 was verified by dual-luciferase reporter gene assay and chromatin immunoprecipitation assay.


      FRZB was low expressed in TNBC tissues and cells. Silencing FRZB promoted cell proliferation, migration, invasion, and EMT and activated JAK/STAT pathway in MDA-MB-468 and MDA-MB-231 cells, but overexpression of FRZB acted opposite effects in MDA-MB-468 and MDA-MB-231 cells. EGR1 was low expressed in TNBC samples and positively correlated with FRZB. Moreover, EGR1 could recover the promotion of silencing FRZB on cell proliferation, migration, invasion, and JAK/STAT pathway in MDA-MB-468 cells, but silencing EGR1 led to the opposite results in MDA-MB-231 cells.


      FRZB was low expressed in TNBC and was regulated by EGR1, and FRZB inhibited TNBC cell growth and invasion by regulating the JAK/STAT3 pathway.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mahdavi M.
        • Nassiri M.
        • Kooshyar M.M.
        • et al.
        Hereditary breast cancer; genetic penetrance and current status with BRCA.
        J Cell Physiol. 2019; 234: 5741-5750
        • Zhang B.
        • Beeghly-Fadiel A.
        • Long J.
        • Zheng W.
        Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.
        Lancet Oncol. 2011; 12: 477-488
        • Bianchini G.
        • Balko J.M.
        • Mayer I.A.
        • Sanders M.E.
        • Gianni L.
        Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
        Nat Rev Clin Oncol. 2016; 13: 674-690
        • Ferlay J.
        • Colombet M.
        • Soerjomataram I.
        • et al.
        Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
        Int J Cancer. 2019; 144: 1941-1953
        • Prat A.
        • Adamo B.
        • Cheang M.C.
        • Anders C.K.
        • Carey L.A.
        • Perou C.M.
        Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
        Oncologist. 2013; 18: 123-133
        • Chen W.
        • Zheng R.
        • Baade P.D.
        • et al.
        Cancer statistics in China, 2015.
        CA Cancer J Clin. 2016; 66: 115-132
        • Yamamura S.
        • Kawakami K.
        • Hirata H.
        • Saini S.
        • Dahiya R.
        Abstract #3402: roles of the Wnt modulator, secreted frizzled-related protein 2 (sFRP2), in human renal carcinoma cells.
        Cancer Res. 2009; 69: 3402
        • Peichel C.L.
        • Kozak C.A.
        • Luyten F.P.
        • Vogt T.F.
        Evaluation of mouse Sfrp3/Frzb1 as a candidate for the lst, Ul, and Far mutants on chromosome 2.
        Mamm Genome. 1998; 9: 385-387
        • Leyns L.
        • Bouwmeester T.
        • Kim S.H.
        • Piccolo S.
        • De Robertis E.M.
        Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer.
        Cell. 1997; 88: 747-756
        • Bahl C.
        • Sharma S.
        • Singh N.
        • Behera D.
        Single nucleotide variations in the Wnt antagonist sFRP3 (rs7775 & rs288326) and sFRP4 (rs1802073 & 1802074) genes and their association with lung cancer risk in North Indians.
        Meta Gene. 2017; 13: 159-168
      1. Fang L., Gao C., Bai R.X., Wang H.F., Du S.Y. Overexpressed sFRP3 exerts an inhibitory effect on hepatocellular carcinoma via inactivation of the Wnt/beta-catenin signaling pathway. Cancer Gene Ther 2020.

        • Ekstrom E.J.
        • Sherwood V.
        • Andersson T.
        Methylation and loss of secreted frizzled-related protein 3 enhances melanoma cell migration and invasion.
        PLoS One. 2011; 6: e18674
        • Wu Z.H.
        • Zhang Y.J.
        • Yue J.X.
        • Zhou T.
        Comprehensive analysis of the expression and prognosis for SFRPs in breast carcinoma.
        Cell Transplant. 2020; 29963689720962479
        • Thiel G.
        • Cibelli G.
        Regulation of life and death by the zinc finger transcription factor Egr-1.
        J Cell Physiol. 2002; 193: 287-292
        • Li Y.B.
        • Guo C.X.
        • Wang Z.C.
        • et al.
        Radiosensitization of breast cancer cells by TRAIL-endostatin-targeting gene therapy.
        Neoplasma. 2013; 60: 613-619
        • Seo B.J.
        • Son J.W.
        • Kim H.R.
        • Hong S.H.
        • Song H.
        Identification of egr1 direct target genes in the uterus by in silico analyses with expression profiles from mRNA microarray data.
        Dev Reprod. 2014; 18: 1-11
        • Crawford N.T.
        • McIntyre A.J.
        • McCormick A.
        • D'Costa Z.C.
        • Buckley N.E.
        • Mullan P.B.
        TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
        Oncogene. 2019; 38: 5971-5986
        • Wong K.M.
        • Song J.
        • Wong Y.H.
        CTCF and EGR1 suppress breast cancer cell migration through transcriptional control of Nm23-H1.
        Sci Rep. 2021; 11: 491
        • Wei L.L.
        • Wu X.J.
        • Gong C.C.
        • Pei D.S.
        Egr-1 suppresses breast cancer cells proliferation by arresting cell cycle progression via down-regulating CyclinDs.
        Int J Clin Exp Pathol. 2017; 10: 10212-10222
        • Pourali L.
        • Taghizadeh A.
        • Sales S.S.
        Mammographic findings in different breast cancer subtypes (luminal – Her2 positive – triple negative).
        Multidiscip Cancer Investig. 2017; 16 (suppl 1): 251-255
        • Kondov B.
        • Milenkovikj Z.
        • Kondov G.
        • et al.
        Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients.
        Open Access Maced J Med Sci. 2018; 6: 961-967
        • Ernst B.
        • Anderson K.S.
        Immunotherapy for the treatment of breast cancer.
        Curr Oncol Rep. 2015; 17: 5
        • Liu N.
        • Yang Z.
        • Liu X.
        • Niu Y.
        Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative.
        Oncotarget. 2017; 8: 55534-55543
        • Wang C.
        • Tan C.
        • Wen Y.
        • et al.
        FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/beta-catenin signaling pathway.
        Cell Death Dis. 2019; 10: 499
        • Quan X.
        • Zhao M.
        • Yang X.
        • Zhu Y.
        • Tian X.
        AP2gamma mediated downregulation of lncRNA LINC00511 as a ceRNA suppresses trophoblast invasion by regulating miR-29b-3p/Cyr61 axis.
        Biomed Pharmacother. 2019; 120109269
        • Qin S.
        • Zhang Z.
        • Li J.
        • Zang L.
        FRZB knockdown upregulates beta-catenin activity and enhances cell aggressiveness in gastric cancer.
        Oncol Rep. 2014; 31: 2351-2357
        • Tao W.
        • Wu J.
        • Zhang Q.
        • et al.
        EGR1 regulates hepatic clock gene amplitude by activating Per1 transcription.
        Sci Rep. 2015; 5: 15212
        • Kowshik J.
        • Baba A.B.
        • Giri H.
        • Deepak Reddy G.
        • Dixit M.
        • Nagini S.
        Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer.
        PLoS One. 2014; 9e109114
        • Hu Y.
        • Hong Y.
        • Xu Y.
        • Liu P.
        • Guo D.H.
        • Chen Y.
        Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
        Apoptosis. 2014; 19: 1627-1636
        • Slattery M.L.
        • Lundgreen A.
        • Hines L.M.
        • et al.
        Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the breast cancer health disparities study.
        Breast Cancer Res Treat. 2014; 147: 145-158